Paclitaxel, Cisplatin, and Veliparib in Treating Patients With Advanced, Persistent, or Recurrent Cervical Cancer
Status:
Completed
Trial end date:
2017-02-11
Target enrollment:
Participant gender:
Summary
This phase I clinical trial studies the side effects and best dose of veliparib when given
together with paclitaxel and cisplatin and to see how well they work in treating patients
with cervical cancer that has spread to other places in the body and usually cannot be cured
or controlled with treatment or that has come back. Drugs used in chemotherapy, such as
paclitaxel and cisplatin, work in different ways to stop the growth of tumor cells, either by
killing the cells, by stopping them from dividing, or by stopping them from spreading.
Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell
growth. Giving more than one drug (combination chemotherapy) and giving chemotherapy together
with veliparib may kill more tumor cells.